Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: CTMX stock price vs SEE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SEE's multiple
Needs SEE P/S.
Implied fair value · at CTMX's multiple
Needs CTMX P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTMX FY 2025 (ended Dec 31, 2025) · SEE FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
CytomX Therapeutics, Inc. · implied price per share
Bear
$0.44
Base
$0.52
Bull
$0.60
SEALED AIR CORP/DE · implied price per share
Bear
$35.69
Base
$41.99
Bull
$48.28
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.03x
3.24x
Net debt / EBITDA
Leverage against operating earnings
20.51x
2.87x
Cash and equivalents
Liquid reserves on the balance sheet
$292.06M
$344.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
IDEAYA Biosciences, Inc.
CTMX vs IDYA
EXELIXIS, INC.
CTMX vs EXEL
GILEAD SCIENCES, INC.
CTMX vs GILD
AMGEN INC
CTMX vs AMGN
AbbVie Inc.
CTMX vs ABBV
BRISTOL MYERS SQUIBB CO
CTMX vs BMY
Avery Dennison Corp
CTMX vs AVY
BERRY GLOBAL GROUP, INC.
CTMX vs BERY
PACKAGING CORP OF AMERICA
CTMX vs PKG
Amcor plc
CTMX vs AMCR
SONOCO PRODUCTS CO
CTMX vs SON
CROWN HOLDINGS, INC.
CTMX vs CCK
$2.99M
$4.01B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe CTMX can reverse its -44.8% revenue decline and rebuild margins from negative territory, then the stock may be worth holding or accumulating near the $3.44-$4.20 band because the current price already sits close to the historical low end; otherwise, SEE screens as the higher-quality business on the provided data.
CTMX trades at a P/S of 10.9x and EV/Revenue of 7.1x despite negative margins and declining revenue, which is a demanding valuation for a business with shrinking top line. Its price of $3.82 sits near the lower end of the historical band of $3.44-$4.20, but the absence of an implied price and upside/downside estimate limits conviction on the valuation case.
Supporting Metrics
